Perils and Pitfalls Regarding Differential Diagnosis and Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma

被引：11

作者：

Diamantidis, Michael D. ^{[1
]}

Myrou, Athena D. ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, AHEPA Hosp, Propedeut Dept Internal Med 1, Dept Haematol, GR-54006 Thessaloniki, Greece

来源：

THESCIENTIFICWORLDJOURNAL | 2011年 / 11卷

关键词：

primary cutaneous anaplastic large-cell lymphoma (PC-ALCL); T-non-Hodgkin lymphoma (T-NHL); CD30(+) T-cell lymphoproliferative disorder (PCLPD); immunohistochemistry; systemic anaplastic large-cell lymphoma (ALCL); anaplastic lymphoma kinase (ALK); cutaneous lymphocyte antigen (CLA); epithelial membrane antigen (EMA); multifocal lesions; disseminated disease; differential diagnosis; treatment; CD30(+) LYMPHOPROLIFERATIVE DISORDERS; MANAGEMENT; THERAPY; ALCL; ETOPOSIDE; PAPULOSIS; DISEASE; PATIENT; SKIN;

D O I：

10.1100/tsw.2011.80

中图分类号：

X [环境科学、安全科学];

学科分类号：

08 ; 0830 ;

摘要：

Primary cutaneous anaplastic large-cell lymphoma (PC-ALCL), belonging to the CD30+ T-cell lymphoproliferative disorders (PCLPDs), is a rare T-cell lymphoma, presenting on the skin and characterized by very good prognosis and response to treatment in the majority of cases. Nevertheless, PC-ALCL must be distinguished from secondary skin lesions in systemic ALCL, which confer a poor prognosis, and other CD30+ PCLPDs, reactive conditions, or borderline cases. Given their rarity and heterogeneity, these entities represent diagnostic and therapeutic challenges, thus requiring a multidisciplinary approach and expertise to ensure appropriate diagnosis and management. There are several perils and pitfalls that exist regarding the differential diagnosis, the possible progression, and the treatment of PC-ALCL. Careful staging, correlation of clinical findings with histopathology and immunopathology, and thorough follow-up are essential in order to achieve a correct diagnosis and proper treatment of the disease.

引用

页码：1048 / 1055

页数：8

共 31 条

[1] Primary and secondary cutaneous CD30+ lymphoproliferative disorders:: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment [J].